Specify a stock or a cryptocurrency in the search bar to get a summary
Zhejiang Starry Pharm Co Ltd
603520Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally. Its contrast agent products include iohexol, iohexol hydrolysate, iohexol iodide, ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate; and fluoroquinolones products, such as levofloxacin, levofloxacin hydrochloride, levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate. The company was founded in 1997 and is headquartered in Taizhou, China. Address: Modern Industrial Cluster Area, Taizhou, China, 317306
Analytics
WallStreet Target Price
76.98 CNYP/E ratio
235.5Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 603520
Dividend Analytics 603520
Dividend growth over 5 years
10 %Continuous growth
–Payout Ratio 5 years average
1 %Dividend History 603520
Stock Valuation 603520
Financials 603520
Results | 2019 | Dynamics |